MEG
TPST icon

Millstone Evans Group’s Tempest Therapeutics TPST Stock Holding History

Millstone Evans Group’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-62
Closed -$590 – 815
2025
Q1 		$590 Hold
62
– – ﹤0.01% 763
2024
Q4 		$668 Buy
+62
New +$800 ﹤0.01% 701

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Millstone Evans Group's TPST Position: Q2 2025 in Review

Millstone Evans Group sold out of Tempest Therapeutics (TPST) in Q2 2025, closing a stake of 62 shares — an estimated $590 sold.

Millstone Evans Group first reported a position in TPST in Q4 2024 and held it in 2 quarters. The position peaked at $668 in Q4 2024. 18 funds tracked by Wall St. Rank hold TPST as of Q2 2025.

  • Millstone Evans Group reported no remaining Tempest Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Millstone Evans Group sold 62 Tempest Therapeutics shares in Q2 2025, an estimated $590.
  • Millstone Evans Group first reported a position in Tempest Therapeutics in Q4 2024 and held it in 2 quarters.
  • Millstone Evans Group's Tempest Therapeutics position peaked at $668 in Q4 2024.
  • 18 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2025.

Based on Millstone Evans Group's 13F filing for Q2 2025, filed 13 Aug 2025.